Give your appropriate patients the opportunity to receive 10 free PROMETRIUM® 100-mg or 200-mg capsules. Simply fill out the form below, then click Submit.

You may order up to 3 voucher packets a month. Each packet contains 8 vouchers, and each voucher can be redeemed for 10 free PROMETRIUM® 100-mg or 200-mg capsules. Be sure to select the number of voucher packets you wish to receive.

Please provide this missing information.

*State License #

*DEA #

    or

*Practitioner First Name

Middle Name

*Practitioner Last Name

Professional Designation

*Address 1

Address 2

*City

*State AK AL AR AZ CA CO CT DC DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MN MO MS MT NC ND NE NH NJ NM NV NY OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

*Zip Code

*Number of Vouchers

1 2 3

How did you hear about the PROMETRIUM® voucher program?

PROMETRIUM® website Journal Ad Mailing Other

*Required information.

Be sure to review your information for accuracy before you click Submit.

This information will only be used for the fulfillment of the requested PROMETRIUM® vouchers and for no other purposes.

Looking for educational materials for your patients? Click here to download.

Please click here for PROMETRIUM® Full Prescribing Information.

PROMETRIUM® (progesterone, USP) Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets, as well as for treatment of secondary amenorrhea.[1]

The most common adverse events reported in patients receiving varying dosages of PROMETRIUM® (100 mg/day to 400 mg/day) were: dizziness, breast pain, headache, abdominal pain, chest pain, and diarrhea.[1]

Transient dizziness may occur in some patients; they should use caution when driving or operating machinery; for these women, bedtime dosing may be advised.[1]

PATIENTS WHO ARE ALLERGIC TO PEANUTS SHOULD NOT USE PROMETRIUM® CAPSULES.[1]

Progestins and estrogens should not be used for the prevention of cardiovascular disease. The Women's Health Initiative reported an increased risk of myocardial infarction, stroke, breast cancer, pulmonary emboli, and deep venous thrombosis in postmenopausal women (ages 50–79) receiving oral conjugated equine estrogens (0.625 mg/day) in combination with medroxyprogesterone acetate (2.5 mg/day) compared to placebo. While products marketed by Solvay Pharmaceuticals, Inc. were not studied in the WHI, in the absence of conclusive data, a conservative view would assume the risks to be similar.[1]

The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during four years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.[1]

Reference:
1. PROMETRIUM® [package insert]. Marietta, Ga: Solvay Pharmaceuticals, Inc.; 2004.